| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.37 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Asthma and chronic obstructive pulmonary disease (COPD)
are major causes of mortality and morbidity worldwide. The current
state-of-art diagnosis and management schemes are suboptimal for
both diseases as the incidence of asthma has risen by 250% over the
last two decades and COPD is estimated to become the third leading
cause of death worldwide within the next decade. Additionally, these
diseases represent a very important threat to global economies in direct
and indirect medical costs and lost working days [1,2]. Asthma is a
chronic inflammatory disorder of the airways associated with airway
hyperresponsiveness that leads to recurrent episodes of wheezing,
breathlessness, chest tightness and coughing. These episodes are
usually associated with widespread, but variable, airflow obstruction
within the lung [1]. Chronic airflow obstruction is also characteristic of
COPD but, in contrast to asthma, is not fully reversible, even under the
action of bronchodilators, and is usually progressive. A combination
of small airway disease -obstructive bronchiolitis - and parenchymal
destruction - emphysema, leads to COPD clinical manifestation [2].
A number of factors influence a person’s risk of developing these
lung diseases, which include host factors, primarily genetic, and
environmental factors, such as allergens and tobacco smoke in asthma
and COPD, respectively
Description
Keywords
Nasal Epithelium Genómica Funcional e Estrutural Proteomics Biomarkers
Pedagogical Context
Citation
J Aller Ther 2012, S7. doi:10.4172/2155-6121.S7-004
